ArticleThe oncologist2026
Clinical and molecular features associated with the presence of brain metastases and survival in patients with advanced thyroid cancer.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrain metastases in advanced thyroid cancer may be underrecognized due to lack of routine brain imaging. We characterized the clinical and molecular features, risk factors, and survival outcomes of patients with non-anaplastic follicular cell-derived thyroid carcinoma (FCDTC) with brain metastases.
methodsThis retrospective cohort study included patients with advanced non-anaplastic FCDTC treated in the Medical Oncology Department at Princess Margaret Cancer Centre between 2007 and 2022. Clinicopathologic and treatment data were extracted from electronic records, and all tumors underwent targeted next-generation sequencing. Risk factors for brain metastasis were assessed using logistic regression, and overall survival was analyzed with Kaplan-Meier and Cox proportional hazards models.
resultsOf 187 patients with advanced non-anaplastic FCDTC, 32 (17%) were diagnosed with brain metastases. Dedicated brain imaging was performed in 56% of patients, and most metastases (78%) were asymptomatic and incidentally detected. Lung metastases were associated with higher risk of developing brain metastases (aOR 8.27, 95% CI 1.87-36.46). ARID2 mutations were enriched in patients with brain metastases (9% vs 1%, P = .02). Survival did not differ between patients with and without brain metastases. Patients with brain metastases who had an ECOG performance status ≥2 (aHR 6.30, 95% CI 1.61-24.64) or ≥4 brain metastases (aHR 4.92, 95% CI 1.45-16.64) had worse survival. Molecular alterations were not predictive of survival.
conclusionBrain metastases occurred more frequently than previously reported. Lung metastases were associated with higher risk of developing brain metastases, and performance status and lesion number were associated with survival. These findings support consideration of brain metastasis screening in advanced thyroid cancer and may inform future prognostic and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.